1. Introduction {#sec1}
===============

Precision medicine calls for better characterization of diseases at molecular level. As the cost of next-generation sequencing (NGS) technology becomes increasingly affordable, more and more efforts have been invested on genome wide observation of genetic changes and gene expression profiles in cancer. NGS-based RNA-sequencing (RNA-seq) is an established and effective screening method in identifying new biomarkers and better understanding cancer biology \[[@B1]\]. Nationwide and international consortia like The Cancer Genome Atlas (TCGA) and the International Cancer Genomics Consortium (ICGC) have generated tremendous amounts of new data and new insights regarding the molecular landscape of many major types of cancer using various high throughput profiling technologies including RNA-seq \[[@B2]--[@B4]\].

Endometrial cancer of the uterus is responsible for about 74,000 deaths of women each year worldwide \[[@B5], [@B6]\]. It is the most common gynecological malignancy in America and other western countries. Among the histologic subtypes, endometrioid carcinoma is the most prevalent, accounting for 75%--85% of all patients. Other types, like serous, mucinous, clear cell and squamous cell carcinomas, are much less common. According to the data from SEER (Surveillance, Epidemiology, and End Results) program at the National Cancer Institute (<https://seer.cancer.gov/>), although the current survival rate of women with endometrial cancer is as high as 81%, annual deaths from endometrial cancer still numbered over 10,000 patients in the United States alone. Furthermore, for over three decades, the age-adjusted death rate of endometrial cancer in the general population has not decreased. Thus, it is imperative to better characterize the molecular details of endometrial cancer using the latest high throughput profiling technology to identify new biomarkers that may enhance our understanding of disease progression and may impact clinical management of this cancer.

The largest effort in interrogating the transcriptome of endometrial cancer is from TCGA \[[@B7]\]; however both the initial comprehensive report from TCGA on endometrial cancer and the follow-up report by others who focused on the RNA-seq data of endometrial cancer in TCGA did not provide transcriptome-wide information on the differentially expressed genes in the scenario of endometrial cancer versus normal endometrial tissue \[[@B7], [@B8]\]. Another effort by Xiong et al. examined the transcriptome profiles of endometrial cancer versus adjacent noncancer tissue, but with 3 patients only \[[@B9]\]. In the current study, we screened paired human endometrioid carcinoma tissues and the adjacent nontumor tissues from 7 patients using RNA-seq technology and compared their gene expression profiles. Further validation was performed by quantitative PCR and immunohistochemistry. Focusing on the overexpressed gene*IGSF9*, we explored its associations with clinicopathologic characteristics in endometrioid endometrial carcinoma.

2. Materials and Methods {#sec2}
========================

2.1. Human Tissue Specimens {#sec2.1}
---------------------------

Two different approaches were used in human tissue specimen procurement. For RNA-seq, freshly harvested, RNAlater-preserved cancer and adjacent noncancer tissues were obtained from 7 patients through frozen section rooms at The Medical Foundation (South Bend, IN). For the follow-up immunohistochemistry study, formalin-fixed and paraffin-embedded (FFPE) blocks from a total of 56 patients were obtained from The Medical Foundation surgical archive. All specimens were collected during the period from 2013 to 2015 via the Harper Cancer Research Institute Tissue Biorepository project. All collection of human tissues from surgically removed uterine endometrial cancer specimens were conducted by The Medical Foundation pathologists. Pathologic diagnoses and classification were initially made by the pathologist on-duty and further reviewed by board-certified pathologists. Informed consent was obtained from all patients. Protocols were approved by the University of Notre Dame Institutional Review Board (IRB) and local hospital IRBs.

2.2. RNA-Sequencing and Data Processing {#sec2.2}
---------------------------------------

For RNA preparation, \~30 mg tissue from each specimen was homogenized using an Omni-TH tissue homogenizer (OMNI International, Kennesaw, GA) in prechilled lysis buffer from the AllPrep RNA/DNA/protein mini kit (Qiagen, Germantown, MD) according to the manufacturer\'s instructions. RNA elution was then quantified with a Nanodrop spectrophotometer (Thermo Fisher) and further analyzed by BioAnalyzer (Agilent) for quality control. Samples with RIN \> 7 were used in RNA-seq library preparation by the Notre Dame Genomics Core Facility. RNA-seq libraries were prepared with nonstranded TruSeq RNA kit from Illumina (San Diego, CA) and sequenced on a HiSeq 4000 sequencer (BGI Hong Kong). The reads generated were paired-end and of length 100-nt. Raw reads were cleaned up by BGI with SOAPnuke to remove adapters and low-quality reads. All other command line software tools were installed and used on the high performance computer cluster at University of Notre Dame Center for Research Computing. FastQC (version 0.11.2) was used to examine the read quality. No further read trimming or filtering was performed. Splicing aware mapping tool, STAR (version 2.4.2a) was used for alignment in 2-pass mode. The resulting BAM files were examined by Qualimap (version 2.2) and then used to count reads per gene with the htseq-count function from HTSeq software (version 0.6.1).

R/Bioconductor packages including DESeq2 were used for gene expression analysis \[[@B10]--[@B12]\]. Dealing with paired samples, we used a multifactor design which includes the sample information by putting the condition of interest (cancer or noncancer) at the end of the design. When the data was treated as from two independent groups, only single factor design was used. For comparison, we also downloaded and reanalyzed the raw RNA-seq data published by Xiong et al. \[[@B9]\] from SRA (NIH Sequence Read Archive) with our own data processing protocol as mentioned above. To identify the most overrepresented biological terms and genes, we made use of the gene classification tool from DAVID Bioinformatics Resources 6.8 \[[@B13]\] (<https://david.ncifcrf.gov>). High classification stringency was used.

To access tumor subgroup gene expression and survival data in The Cancer Genome Atlas (TCGA) project, we used the web interface of UALCAN \[[@B14]\] and part of the processed data from UALCAN. UALCAN uses TCGA level 3 RNA-seq and clinical data from 33 cancer types. The expression level was normalized as transcripts per million reads (TMP) for comparison across groups and individuals.

2.3. Quantitative PCR {#sec2.3}
---------------------

Taqman® gene expression assays were used in quantitative PCR. The primers and probe set for the*IGSF9* gene and reference control gene*ACTB* were bought from Life Technologies (Carlsbad, CA). RNA sample preparation and cDNA synthesis used TRIzol reagent and SuperScript II reagent, respectively, from Life Technologies. The q-PCR reaction was run on an ABI StepOnePlus real time thermal cycler (Life Technologies). Quantification was calculated with the ΔΔCt method using control samples and the expression of the reference gene*ACTB*for normalization \[[@B15]\].

2.4. Immunohistochemistry {#sec2.4}
-------------------------

The immunohistochemistry procedure is as previously described \[[@B16]\]. FFPE tissue sections (5 *μ*m in thickness) were dewaxed in xylene and then rehydrated. Heat induced epitope retrieval was performed with citrate buffer (pH 6.0). Primary antibodies for IGSF9 (catalog number: NBP1-93676, 1 : 200 diluted) and Ki67 (catalog number: ab15580, 1 : 500 diluted) were bought from NOVUS Biologicals (Littleton, CO) and Abcam (Cambridge, MA), respectively. Polymer-based chromogen visualization system used the ImmPRESS™ HRP anti-rabbit IgG product from Vector Laboratories (Burlingame, CA).

2.5. Image Analysis and Quantification {#sec2.5}
--------------------------------------

All immunohistochemistry slides were scanned and analyzed with the digital pathology system, including Aperio ScanScope CS, eSlide manager, and image analysis tools, made by Leica Biosystem (Chicago, Illinois). Quantification of IGSF9 used a macro built from the pixel counting algorithm (version 1), which reports the percentage of total number of positively stained pixels over total number of pixels analyzed. Cellular quantification nuclear stain algorithm (version 9) was used to make a macro to count positive cell percentage of total number of tumor cells analyzed in Ki67 immunostains.

2.6. Statistical Analysis {#sec2.6}
-------------------------

Rstudio and related R packages were used to perform all the statistical analyses involving RNA-seq data downstream processing, clinical pathological data, and IHC results. Significance level was set at *p* value \< 0.05, while in screening the long gene lists from RNA-seq, adjusted *p* values were described in the results. Principle component analysis was used in analyzing the variance in overall RNA-seq counts. Wald test was used when comparing differential gene expression as implemented in DESeq2 package. When comparing means of two groups in clinical and IHC, nonparametric method Wilcoxon rank sum test (also known as Mann--Whitney *U* test) was used. Correlation tests used Pearson\'s method as implemented in base R and the*psych* package. Survival analysis used Kaplan-Meier method and log-rank test.

3. Results {#sec3}
==========

3.1. Gene Expression Profiles of Endometrioid Endometrial Carcinoma and Benign Adjacent Tissues via RNA-seq {#sec3.1}
-----------------------------------------------------------------------------------------------------------

RNA-seq was performed for a total of 7 patients with both cancer tissues and adjacent benign endometrial tissues available. Patient ages ranged from 48 to 78. All specimens were from the same major histological type, endometrioid endometrial carcinoma; two patients were at histological grade I and five at grade II, all at clinical stage I (FIGO, 2009). On average, 17.2 million reads were produced from each of the 14 libraries. Sequencing read quality was examined by FastQC, all with a Phred score above 20. Alignment or mapping quality metrics as produced by Qualimap over the output BAM files from alignment with STAR are listed in Suppl. [Table 1](#supplementary-material-1){ref-type="supplementary-material"}.

While exploring the gene count data, plotting the top two components from principle component analysis did not reveal any clustering trend in the 7 cancer samples versus the 7 controls ([Figure 1(a)](#fig1){ref-type="fig"}). Using DESeq2 as the main tool, we sought to find the differential expression of genes in cancer versus the control with two different approaches: (1) using the pairing information in the samples, (2) without considering the pairing information.

With the first approach, when comparing cancer tissues with noncancer controls, a total of 665 genes (357 up and 308 down) were identified as differentially expressed at the statistical significance level of adjusted (for multiple comparison) *p* value \< 0.05. The entire list of differentially expressed genes is given in Suppl. [Table 2](#supplementary-material-1){ref-type="supplementary-material"}. On the top of gene list ranked by ascending adjusted *p* value there are*EGR1, FOSB, PTPRT, SELE, FOS, ENPP2, TFPI, ZFP36,*and others. Those with adjusted *p* value \< 0.01 and log2 fold change (L2FC) \>2 were labeled in the volcano plot in [Figure 1(b)](#fig1){ref-type="fig"}. TUBB3 is the most increased (L2FC = 2.177). With a cutoff at adjusted *p* value \< 0.01, we obtained a list of 66 genes ([Figure 2](#fig2){ref-type="fig"}), which was used for analysis with NIH DAVID as described below.

Using the second method, the 14 samples were treated as two independent groups, cancer versus control, with pairing information ignored, then only 4 genes were found to be differentially expressed at adjusted *p* value \< 0.05, including*IGSF9, c10orf35*, and*ZNF710* genes overexpressed and the*HHATL* gene downregulated in cancer versus control. The normalized counts of these 4 genes were plotted in Figures [1(c)](#fig1){ref-type="fig"}--[1(f)](#fig1){ref-type="fig"} and the full list of genes is given in Suppl. [Table 3](#supplementary-material-1){ref-type="supplementary-material"}. Reanalysis of the RNA-seq study by Xiong et al. on paired cancer and normal tissues from 3 endometrial cancer patients produced another list of differentially expressed genes (Suppl. [Table 4](#supplementary-material-1){ref-type="supplementary-material"}) \[[@B9]\].

With the aforementioned list of top 66 genes that were taken from the differentially expressed genes cutoff at adjusted *p* value \< 0.01, we performed the analysis with the gene function classification tool from NIH DAVID \[[@B17]\], which has the capability of addressing the enriched and redundant relationships among many-genes-to-many-terms and can reduce the complexity of gene list. Out of the 66 genes, 5 genes, that is,*VSIG2, PTPRT, PRTG, IGSF9*, and*PTPRF*([Figure 3](#fig3){ref-type="fig"}), were found to share functional similarity and form the only enriched cluster, with an enrichment sore of 0.96. Among them,*IGSF9* is the one that increased most in terms of log2 folds. This result from the gene function classification assay with DAVID plus the short list of differentially expressed genes we obtained when treating the samples as 2 independent groups prompted us to further evaluate the expression of IGSF9 with immunohistochemistry on human endometrial cancer tissues.

3.2. IGSF9 Expression in Endometrial Tissue and Endometrioid Carcinoma {#sec3.2}
----------------------------------------------------------------------

The first study on IGSF9 expression was on the developing nervous system in mouse and human \[[@B18]\]; however to date there are no published data detailing IGSF9 expression in endometrial tissue. We first performed quantitative PCR to confirm the differential expression of IGSF9 in cancer versus noncancer endometrial tissues. With 3 paired RNA samples from the RNA-seq project, the relative expression in cancer tissue was found to be over 6 folds compared to adjacent tissue ([Figure 4(a)](#fig4){ref-type="fig"}). IGSF9 is also one of differentially expressed genes identified by our reanalysis of the RNA-seq data from Xiong et al. For side-by-side comparison, we plotted their normalized counts ([Figure 4(b)](#fig4){ref-type="fig"}).

As further characterization of IGSF9 expression in relation to cancer microscopic features requires immunohistochemistry, we evaluated IGSF9 expression at protein level in FFPE materials from 56 patients. Normal endometrial stroma and glands usually stain negative or weak while endometrioid carcinoma stained stronger ([Figure 4(c)](#fig4){ref-type="fig"}). The staining pattern is both membranous and cytoplasmic, but not the entire membrane, with uneven distribution inside the cells, often concentrated on one end of the stained cells. Some specimens show a punctate and particulate perinuclear staining pattern.

3.3. Correlation of IGSF9 Expression with Clinical Pathologic Features {#sec3.3}
----------------------------------------------------------------------

The association of IGSF9 expression with clinicopathologic characteristics of these patients was systematically examined in our collection of 56 patients with endometrial cancer, which were aged from 39 to 94 years, with a median of 64. All patients were diagnosed as endometrioid carcinoma, 28 at grade I, and 28 at grade II in histologic grading ([Table 1](#tab1){ref-type="table"}, Figures [5(a)](#fig5){ref-type="fig"}-[5(b)](#fig5){ref-type="fig"}) \[[@B19]\]. As for clinical stages, 46 patients were at stage I, three at stage II, and seven at stage III. Tumor size, the depth of myometrial invasion, tumor cell labeling of proliferation marker Ki67 (Figures [5(c)](#fig5){ref-type="fig"}-[5(d)](#fig5){ref-type="fig"}), and the presence or absence of lymphovascular invasion were recorded as part of clinical and pathologic data.

The positivity of IGSF9 expression as determined by immunohistochemistry (Figures [5(e)](#fig5){ref-type="fig"}-[5(f)](#fig5){ref-type="fig"}) was presented in decimal format. Among the cases evaluated were eight patients for which both cancer and control (normal/noncancerous) tissues were available. Paired comparison of relative IGSF9 expression shows significantly enhanced staining in cancer tissues relative to controls with values of 0.448 versus 0.200, respectively (*p* value = 0.008 by the Wilcoxon test) ([Figure 6(a)](#fig6){ref-type="fig"}). Comparison of the all the cancer tissues with the 8 control tissues showed a similar trend ([Figure 6(b)](#fig6){ref-type="fig"}) with statistical significance (*p* value = 0.002 by the Wilcoxon test).

A trend was observed in which IGSF9 positivity is higher in histological grade II (G2) relative to grade I (G1) ([Figure 6(c)](#fig6){ref-type="fig"}), but the results are not statistically significant. No association was found in relation to clinical staging and lymphovascular invasion (Figures [6(d)](#fig6){ref-type="fig"} and [6(e)](#fig6){ref-type="fig"}). Interestingly, however, statistically significant difference was obtained when comparing the IGSF9 positivity between patients without any degree of myometrial invasion and those with myometrial invasion (0.151 versus 0.395; *p* value = 0.013 by the Wilcoxon test) ([Figure 6(f)](#fig6){ref-type="fig"}).

The correlation of IGSF9 positivity with other continuous variables, such as age, tumor size in cm, depth of myometrium invasion as percentage of total myometrium thickness, and Ki67 labeling index were plotted in [Figure 7](#fig7){ref-type="fig"}. IGSF9 expression has somewhat of a correlation with Ki67 labeling index, but not statistically significant. However the positive correlation of tumor size with depth of myometrium invasion (coefficient = 0.412, *p* value = 0.002) and that of Ki67 with depth of myometrium invasion (coefficient = 0.360, *p* value = 0.006) were statistically significant.

3.4. IGSF9 Expression Status in RNA-seq Data from TCGA {#sec3.4}
------------------------------------------------------

As a way of in silico validation, we surveyed the expression of*IGSF9* in TCGA RNA-seq dataset via the web portal of UALCAN \[[@B14]\]. As of November 2017, normalized RNA expression data from 33 types of cancer are available, but not all have proper amount of normal controls for comparison.*IGSF9*had higher expression in uterine corpus endometrial cancer (UCEC) tissues and 7 other types of cancers compared to their corresponding normal controls ([Table 2](#tab2){ref-type="table"}). In contrast,*IGSF9* expression is lower in cancer versus normal control in rectum adenocarcinoma and colon adenocarcinoma ([Table 2](#tab2){ref-type="table"}).

UALCAN contains reprocessed RNA-seq data from 546 UCEC tissues and 35 normal endometrial tissues. Out of that, 23 patients provided both cancer and normal tissues.*IGSF9* mRNA expression was found to be higher in both the comparison of all cancer versus normal control (*p* \< 0.001 by Wilcoxon test) and comparison of paired cancer versus normal from the same patients (*p* \< 0.001 by Wilcoxon test) (Figures [8(a)](#fig8){ref-type="fig"} and [8(b)](#fig8){ref-type="fig"}).

A total of 543 endometrial cancer patients with RNA-seq and overall outcome data were used for Kaplan-Meier survival analysis. Overexpression of*IGSF9* (top 25%) was associated with poor survival ([Figure 8(c)](#fig8){ref-type="fig"}, log-rank test, *p* = 0.017). A statistically significant association of*IGSF9* overexpression and poor overall survival was also observed in thymoma, skin cutaneous melanoma, and brain lower grade glioma ([Table 2](#tab2){ref-type="table"}).

4. Discussion {#sec4}
=============

To find differentially expressed genes between groups of specimens, RNA-seq is a very powerful tool as it is high throughput and reliable in quantification \[[@B10], [@B20]\]. For gene expression profiling with RNA-seq, TCGA has data from the largest number of patients \[[@B2]\]. The reports and datasets from TCGA are a rich resource for evaluation of genetic variations or molecular markers of endometrial cancer. Based on their comprehensive findings on somatic copy number alterations and exome sequencing, a new molecular classification system was proposed for endometrial cancer \[[@B7]\]. However, limited evaluation of the mRNA expression data was provided \[[@B7], [@B8]\]. By design, the raw RNA-seq data and clinicopathologic characteristics in all the TCGA projects are open to researchers who are interested in further analyses. Noticeably, many secondary online resources based on TCGA datasets (e.g., the UALCAN website) have recently appeared and greatly eased the use of these data \[[@B14], [@B21]\]. The report by Dellinger and colleagues utilized TCGA data to show that L1CAM is an independent predictor of poor survival in endometrial cancer \[[@B22]\].

The lack of information from normal tissues or benign lesions in RNA-seq data from the initial TCGA endometrial cancer publication piqued our interest and others as well. Xiong and colleagues used RNA-seq to evaluate both mRNA and microRNA expression profiles in three patients with both cancer and noncancer tissues \[[@B9]\]. In addition to mRNA and microRNA expression profiles, their study also performed genetic variation calling from RNA-seq data, which is a feasible but less established approach \[[@B23]\].

In the current study, our RNA-seq with paired cancer and control tissues from 7 endometrioid carcinoma patients discovered a unique set of differentially expressed genes. For example, our reanalysis of Xiong\'s data identified*WISP2 (CCN5)* (log2 fold change −7.12; Suppl. [Table 4](#supplementary-material-1){ref-type="supplementary-material"}) as a highly differentially expressed gene. It is reported to be a tumor suppressor; the deficiency of*WISP2*promotes breast cancer growth \[[@B24]\] and*WISP2* RNA expression was decreased in 79% of human colon cancers \[[@B25]\], but no studies of*WISP2* in endometrial cancer have been reported. The*TUBB3* gene is the most increased gene on our list of genes ([Figure 1(b)](#fig1){ref-type="fig"}) from our own patient materials.*TUBB3* encodes class III *β*-tubulin and its overexpression has been linked to resistance to paclitaxel and correlated with poor survival in ovarian, breast, gastric, and non-small-cell lung cancers and unknown primary tumors \[[@B26], [@B27]\]. This finding was not confirmed in endometrial cancer and class III *β*-tubulin expression was also not correlated with clinicopathologic characteristics \[[@B27], [@B28]\].

Facing the long list of differentially expressed genes, tools for functional profiling are often used to extract biological meaning from such data. RNA-seq specific analysis packages like GOseq and SeqGSEA are available \[[@B29]\]. Our use of the gene functional classification tool in the NIH DAVID package and our top 66 genes provided only one cluster of genes, and treating our paired samples as two independent groups further narrowed the gene list. As*IGSF9* is the only common gene from both analyses, we focused on IGSF9 and explored the association of IGSF9 protein expression with clinicopathological characteristics in endometrioid endometrial carcinoma.

IGSF9 was first cloned and characterized as a member of the immunoglobulin superfamily expressed in a wide variety of tissues in human and mouse \[[@B18]\]. Structurally, it contains five Ig domains, two fibronectin III domains, a single transmembrane domain, and an intracellular C-terminal and it was found to be related to dendrite arborization in the brain \[[@B30]\]. To date, there are no published reports on IGSF9 in any type of cancer tissue. Existing studies of IGSF9 are very limited (10 papers in PubMed as of January 2018). Our study is the first to investigate the association of its expression with cancer, but its expression and mutation profiles could be assessed via searching online databases, such as the Human Protein Atlas project (<http://www.proteinatlas.org>), GTEx (<https://GTExPortal.org>), and the Catalog of Somatic Mutations in Cancer (COSMIC, <http://cancer.sanger.ac.uk/cosmic>).

The expression pattern as revealed by our immunohistochemical analyses in endometrioid carcinoma confirms the localization of IGSF9 on the cellular membrane and in the cytoplasm. We confirmed the differential expression of IGSF9 in cancer versus noncancer tissues with materials from a cohort of 56 patients. The expression of IGSF9 is higher in cancer than that in normal or benign endometrial tissue. The positivity of IGSF9 is also higher in cancer with myometrium invasion than those without, likely an indicator of cancer aggressiveness. However, as these observations were based on the small and retrospective cohort of patients available, further studies on larger and prospective cohorts were needed. Analysis of the expression data from TCGA as we surveyed with UALCAN provided the necessary support. These data confirmed that*IGSF9*is overexpressed in cancerous versus normal endometrial tissue as well as in 7 additional major cancer types as well. Interestingly we observed the opposite relationship in colorectal cancer, wherein*IGSF9* was expressed at lower levels in cancer versus normal, suggesting a topic to be further studied.

A limitation of the current study is our lack of access to survival data for our local cohort of 56 patients. However, analysis of publicly available TCGA RNA-seq data via UALCAN provided further support for our initial finding and enabled survival analyses. Overexpression of*IGSF9* is an indicator of poor prognosis in endometrial cancer. Moreover,*IGSF9* overexpression is also associated with poor prognosis in several other cancer types, including brain lower grade glioma, skin cutaneous melanoma, and thymoma, suggesting that the significance of*IGSF9* in cancer pathology is likely not limited to endometrial cancer.

5. Conclusions {#sec5}
==============

We identified via RNA-seq a list of differentially expressed genes in endometrioid endometrial carcinomas versus noncancer controls. Focusing on*IGSF9*, an adhesion molecule that has not been characterized in connection with cancer pathology, we confirmed the overexpression of IGSF9 in endometrial cancer and found an association with myometrial invasion and poor outcome. These studies provide preliminary support for consideration of IGSF9 as a new biomarker in endometrial cancer with potential utility in diagnostics, prognostics, and therapeutics. Further studies on the role of IGSF9 in cancer pathology are warranted.
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![*RNA-seq identifies differentially expressed genes in endometrioid carcinoma*. (a) Principle component analysis showing the distance of variance among all the 14 samples from 7 patients, no obvious clustering for cancer versus noncancerous control; (b) volcano plot depicting the number of differentially expressed genes based on their *p* values and log2 fold change in the analysis of 7 pairs of samples; (c), (d), (e), and (f) normalized counts from the top 4 genes obtained by comparing the control and cancer tissues as two independent groups.](JO2018-2439527.001){#fig1}

![*Heat map of the top 66 differentially expressed genes*. Genes shown were selected by the adjusted *p* value \< 0.01 in ascending order in the output of DESeq2 analysis on RNA-seq data from 7 pairs of samples (cancer or control). Colored legend indicates patient code, condition (cancer or control), and the relative expression level.](JO2018-2439527.002){#fig2}

![*Gene functional classification*. With either medium or high stringency, the gene functional classification tool from NIH DAVID bioinformatics resource produced only one cluster consisting of 5 genes when fed with 66 genes at adjust *p* value \< 0.01 as shown in the Supplementary [Table 2](#supplementary-material-1){ref-type="supplementary-material"}. Columns are genes names and rows show the related functional categories shared by the genes indicated by the blue dots.](JO2018-2439527.003){#fig3}

![*Expression of IGSF9 in normal endometrium and endometrial carcinoma*. (a) Q-PCR measurement of*IGSF9* from RNA samples of three paired cancer and normal tissues; the Wilcoxon signed rank test gives *p* value = 0.25, while the paired *t*-test gives *p* value = 0.038. (b) Reanalysis of published RNA-seq data from Xiong et al. \[[@B9]\]; the Wald test gives *p* value = 6.80*E* − 10 and adjusted *p* value = 1.27*E* − 07. (c) IHC staining of IGSF9, the right half is noncancerous endometrial glands with weak brown stain, while the left side cancer cells stained strongly brown indicating higher level of expression.](JO2018-2439527.004){#fig4}

![*Histopathological and immunohistochemical evaluation of endometrial carcinoma*. (a) and (b) H&E stain of endometrioid endometrial carcinoma, histological grades I and II, respectively; (c) and (d) Ki67 stain on grade I and II sections, respectively; (e) and (f) IGSF9 stain on grade I and II sections, respectively. Both immunostains were quantified with the image analysis tools from Aperio digital pathology system. Numeric data were used in statistical analysis.](JO2018-2439527.005){#fig5}

![*IGSF9 expression in association with categorical clinicopathologic features*. (a) Comparison of IGSF9 positivity in 8 pairs endometrioid carcinoma and noncancerous endometrial epithelia (*p* value = 0.008). (b) Comparison between noncancerous tissues and all the endometrioid carcinoma tissues from 56 patients (*p* value = 0.002). (c) Histological grade I (G1) versus grade II (G2). (d) Clinical stages. (e) Lymphovascular invasion. (f) Myometrial invasion (*p* value = 0.013).](JO2018-2439527.006){#fig6}

![*IGSF9 expression in association with continuous clinicopathologic features*. Scatter plots showing the pairwise correlations of age (years), tumor size (diameter in cm), depth of myometrium invasion (percentage of the entire myometrium thickness), Ki67 label index (positive percentage of tumor cells), and IGSF9 positivity (positive percentage of analyzed pixels) with each other in the off-diagonals. Loess smoothed (red) and linear (green) fit lines were superimposed on these plots. Each parameter was named in the principal diagonal overlaid with density and rug plots of that parameter. Depth of myometrial invasion correlated with tumor size (coefficient = 0.412, *p* value = 0.020) and Ki67 labeling index (coefficient = 0.360, *p* value = 0.006).](JO2018-2439527.007){#fig7}

![*IGSF9 expression in TCGA endometrial cancer project*. (a) Normalized RNA-seq data for*IGSF9*, transcripts per million (TMP), clinical data of 546 patients cancer specimen versus 35 normal tissues (*p* value \< 0.001). (b) comparison of 23 patients with RNA-seq data from both cancer tissue and normal control (*p* value \< 0.001). (c) Kaplan-Meier survival analysis of 543 patients with IGSF9 expression and outcome data. Log-rank test, *p* value = 0.017.](JO2018-2439527.008){#fig8}

###### 

Clinicopathological characteristics of patients in IHC study.

  Parameters                          Category/measurement    
  ----------------------------------- ----------------------- ----
  Age, mean ± SD, range (year)        64.3 ± 10.7 (39--94)    
  Tumor size, mean ± SD, range (cm)   4.34 ± 2.33 (0.3--12)   
  Clinical stage                      I                       46
  II                                  3                       
  III                                 7                       
  Histologic type                     Endometrioid            56
  Serous                              0                       
  Histologic grade                    G1                      28
  G2                                  28                      
  G3                                  0                       
  Myometrium invasion                 Absent                  3
  Present                             53                      
  Lymphovascular invasion             Absent                  49
  Present                             7                       

###### 

IGSF9 expression and survival correlation in TCGA RNA-seq dataset.

  ----------------------------------------------------------------------------------------------------------------------------------------------------
  Abbrev.   Cancer type                                                        Sample size^(1)^        Expression level^(2)^   Overall survival^(3)^
  --------- ------------------------------------------------------------------ ----------------------- ----------------------- -----------------------
  BLCA      Bladder urothelial carcinoma                                       Normal (*n* = 19)\      Up                      \-
                                                                               Tumor (*n* = 408)                               

  BRCA      Breast invasive carcinoma                                          Normal (*n* = 114)\     Up                      \-
                                                                               Tumor (*n* = 1094)                              

  CESC      Cervical squamous cell carcinoma and endocervical adenocarcinoma   Normal (*n* = 3)\       Up                      \-
                                                                               Tumor (*n* = 305)                               

  CHOL      Cholangiocarcinoma                                                 Normal (*n* = 9)\       Up                      \-
                                                                               Tumor (*n* = 36)                                

  COAD      Colon adenocarcinoma                                               Normal (*n* = 41)\      Down                    \-
                                                                               Tumor (*n* = 286)                               

  HNSC      Head and neck squamous cell carcinoma                              Normal (*n* = 44)\      Up                      \-
                                                                               Tumor (*n* = 520)                               

  LGG       Brain lower grade glioma                                           Grade II (*n* = 248)\   \-                      Yes
                                                                               Grade III (*n* = 265)                           

  LUSC      Lung squamous cell carcinoma                                       Normal (*n* = 59)\      Up                      \-
                                                                               Tumor (*n* = 515)                               

  READ      Rectum adenocarcinoma                                              Normal (*n* = 11)\      Down                    \-
                                                                               Tumor (*n* = 166)                               

  SKCM      Skin cutaneous melanoma                                            Normal (*n* = 1)\       \-                      Yes
                                                                               Tumor (*n* = 472)                               

  THCA      Thyroid carcinoma                                                  Normal (*n* = 60)\      Up                      \-
                                                                               Tumor (*n* = 505)                               

  THYM      Thymoma                                                            Normal (*n* = 2)\       \-                      Yes
                                                                               Tumor (*n* = 121)                               

  UCEC      Uterine corpus endometrial cancer                                  Normal (*n* = 35)\      Up                      Yes
                                                                               Tumor (*n* = 546)                               
  ----------------------------------------------------------------------------------------------------------------------------------------------------

*Notes*. ^(1)^The number of normal versus tumor samples, except for LGG. ^(2)^"Up" or "Down" indicates significant expression level changes, tumor versus normal; dash indicates no significant change. ^(3)^Kaplan-Meier analysis; "Yes" indicates that higher expression of IGSF9 is related to poor overall survival.

[^1]: Academic Editor: Akira Hara
